GlassScriptPhysician profile
Thomas J Beggins
NPI 1235140104
$1,420.34
in general payments reported to CMS, 2019-2025
19 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $160 · 2021: $205 · 2022: $127 · 2023: $191 · 2024: $141 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $393.87 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $191.15 | 2019-2021 | |
| Alcon Vision LLC | $121.48 | 2022-2025 | Tryptyr, Clareon Panoptix Pro, Argos |
| Amgen INC. | $118.85 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $108.39 | 2022-2023 | Tepezza |
| Astellas Pharma US INC | $72.31 | 2023 | |
| Oyster Point Pharma, INC. | $65.42 | 2024-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $56.94 | 2019 | |
| Abbvie INC. | $42.84 | 2024-2025 | |
| Allergan, INC. | $38.78 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $38.51 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.85 | 2024 | Acthar |
| Sun Pharmaceutical Industries INC. | $28.24 | 2019 | |
| Genentech USA, INC. | $24.61 | 2023 | Vabysmo |
| Rxsight INC | $22.33 | 2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $20.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.41 | 2020 | |
| Dompe US, INC. | $15.05 | 2022 | |
| Eyepoint US, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Beggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.